How to buy Pharvaris N-V stock | $20.5

Pharvaris N.V is a biotechnology business based in the US. Pharvaris N-V shares (PHVS) are listed on the NASDAQ and all prices are listed in US Dollars. Pharvaris N-V employs 14 staff and has a market cap (total outstanding shares value) of 0.00.

Pharvaris N-V stock price (NASDAQ: PHVS)

Use our graph to track the performance of PHVS stocks over time.

Pharvaris N-V shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$20.50
52-week range	$13.14 - $42.86
50-day moving average	$17.14
200-day moving average	$24.32
Wall St. target price	$47.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Pharvaris N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Pharvaris N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Pharvaris N.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pharvaris N-V price performance over time

Historical closes compared with the close of $20.5 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	25.77%
3 months (2021-05-04)	-17.34%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Pharvaris N-V financials

Gross profit TTM	$0
Return on assets TTM	-25.69%
Return on equity TTM	-45.41%
Profit margin	0%
Book value	$7.12
Market capitalisation	$562.9 million

TTM: trailing 12 months

Shorting Pharvaris N-V shares

There are currently 114,119 Pharvaris N-V shares held short by investors – that's known as Pharvaris N-V's "short interest". This figure is 77.8% down from 514,756 last month.

There are a few different ways that this level of interest in shorting Pharvaris N-V shares can be evaluated.

Pharvaris N-V's "short interest ratio" (SIR)

Pharvaris N-V's "short interest ratio" (SIR) is the quantity of Pharvaris N-V shares currently shorted divided by the average quantity of Pharvaris N-V shares traded daily (recently around 17449.388379205). Pharvaris N-V's SIR currently stands at 6.54. In other words for every 100,000 Pharvaris N-V shares traded daily on the market, roughly 6540 shares are currently held short.

To gain some more context, you can compare Pharvaris N-V's short interest ratio against those of similar companies.

• IGM Biosciences (IGMS.US): 22.45
• CNS Pharmaceuticals (CNSP.US): 0.49
• Moleculin Biotech (MBRX.US): 3.13

However Pharvaris N-V's short interest can also be evaluated against the total number of Pharvaris N-V shares, or, against the total number of tradable Pharvaris N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pharvaris N-V's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Pharvaris N-V shares in existence, roughly 0 shares are currently held short) or 0.016% of the tradable shares (for every 100,000 tradable Pharvaris N-V shares, roughly 16 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pharvaris N-V.

Find out more about how you can short Pharvaris N-V stock.

Pharvaris N-V share dividends

We're not expecting Pharvaris N-V to pay a dividend over the next 12 months.

Pharvaris N-V overview

Pharvaris N. V. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.

Frequently asked questions

What percentage of Pharvaris N-V is owned by insiders or institutions?
Currently 13.131% of Pharvaris N-V shares are held by insiders and 66.561% by institutions. How many people work for Pharvaris N-V?
Latest data suggests 14 work at Pharvaris N-V. When does the fiscal year end for Pharvaris N-V?
Pharvaris N-V's fiscal year ends in December. Where is Pharvaris N-V based?
Pharvaris N-V's address is: J.H. Oortweg 21, Leiden, Netherlands, 2333 CH